Atherogenesis. Curr. Opin. Lipidol. 2002, 13, 46170. Tabas, I.; Williams, K.J.; Boren, J. Subendothelial lipoprotein retention as the initiating approach in atherosclerosis: Update and therapeutic implications. Circulation 2007, 116, 1832844. Klop, B.; Castro Cabezas, M. Chylomicrons: A crucial biomarker and risk aspect for cardiovascular illness and for the understanding of obesity. Curr. Cardiovasc. Danger. Rep. 2012, six, 274. Subramanian, S.; Chait, A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim. Biophys. Acta 2012, 1821, 81925. Pacifico, L.; Anania, C.; Osborn, J.F.; Ferraro, F.; Bonci, E.; Olivero, E.; Chiesa, C. Low 25(OH)D3 levels are associated with total adiposity, metabolic syndrome, and hypertension in Caucasian kids and adolescents. Eur. J. Endocrinol. 2011, 165, 60311. Proctor, S.D.; Vine, D.F.; Mamo, J.C. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 2162167. Watts, G.F.; Chan, D.C.; Barrett, P.H.; Martins, I.J.; Redgrave, T.G. Preliminary experience with a new steady isotope breath test for chylomicron remnant metabolism: A study in central obesity. Clin. Sci. (Lond.) 2001, 101, 68390. Taskinen, M.R.; Adiels, M.; Westerbacka, J.; Soderlund, S.; Kahri, J.; Lundbom, N.; Lundbom, J.; Hakkarainen, A.; Olofsson, S.O.; Orho-Melander, M.; et al. Dual metabolic defects are needed to generate hypertriglyceridemia in obese subjects. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 2144150. Caron, S.; Verrijken, A.; Mertens, I.; Samanez, C.H.; Mautino, G.; Haas, J.T.; Duran-Sandoval, D.; Prawitt, J.; Francque, S.; Vallez, E.; et al. Transcriptional activation of apolipoprotein CIII expression by glucose might contribute to diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 51319. Mamo, J.C.; Watts, G.F.; Barrett, P.H.; Smith, D.; James, A.P.; Pal, S. Postprandial dyslipidemia in males with visceral obesity: An effect of decreased LDL receptor expression Am.Vibostolimab In stock J.Isovitexin Purity Physiol.PMID:30125989 Endocrinol. Metab. 2001, 281, E626 632. Castro Cabezas, M.; Erkelens, D.W. The direct way from gut to vessel wall: Atheroinitiation. Eur. J. Clin. Invest. 1998, 28, 50405. Jorgensen, A.B.; Frikke-Schmidt, R.; West, A.S.; Grande, P.; Nordestgaard, B.G.; Tybjaerg-Hansen, A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 2012, doi:ten.1093/eurheartj/ehs431.Nutrients 2013, 5 69.70. 71.72.73.74. 75.76.77.78.79.80.81. 82. 83.Senti, M.; Nogues, X.; Pedro-Botet, J.; Rubies-Prat, J.; Vidal-Barraquer, F. Lipoprotein profile in males with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992, 85, 306. Vogel, R.A.; Corretti, M.C.; Plotnick, G.D. Impact of a single high-fat meal on endothelial function in healthful subjects. Am. J. Cardiol. 1997, 79, 35054. Lundman, P.; Eriksson, M.; Schenck-Gustafsson, K.; Karpe, F.; Tornvall, P. Transient triglyceridemia decreases vascular reactivity in young, healthful males without the need of risk elements for coronary heart illness. Circulation 1997, 96, 3266268. Steinberg, H.O.; Tarshoby, M.; Monestel, R.; Hook, G.; Cronin, J.; Johnson, A.; Bayazeed, B.; Baron, A.D. Elevated circulating free of charge fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest. 1997, 100, 1230239. Van Oostrom, A.J.; van Wijk, J.; Cas.